Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PMVP - PMV Pharmaceuticals, Inc.

IEX Last Trade
1.52
0   0%

Share volume: 1,400
Last Updated: Fri 27 Dec 2024 06:20:12 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.40%

PREVIOUS CLOSE
CHG
CHG%
$1.52
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-2.65%
1 Month
-7.55%
3 Months
-1.01%
6 Months
-11.45%
1 Year
-52.27%
2 Year
-83.16%
Key data
Stock price
$1.52
P/E Ratio 
0.00
DAY RANGE
$1.49 - $1.52
EPS 
$0.00
52 WEEK RANGE
$1.49 - $3.47
52 WEEK CHANGE
-$53.63
MARKET CAP 
80.886 M
YIELD 
N/A
SHARES OUTSTANDING 
51.520 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.69
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$205,597
AVERAGE 30 VOLUME 
$223,950
Company detail
CEO: David H. Mack
Region: US
Website: pmvpharma.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

PMV Pharmaceuticals, Inc. engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.

Recent news